Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1056€
Last updated
24/07/2025 - 16:41
-5,88%
€10.5M
Sales in 2023
+42%
Sales growth in 2023
excluding exchange rates
+52%
PPU growth in 2023
excluding exchange rates
Events and
Presentations
Financial
Results
Governance
Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure
Voting Rights Information – June 2025
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025
Voting Rights Information – May 2025
Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation
News
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership
Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S.
Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 64,702,127
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
Guillaume Cuvillier
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France
• Exco Socodec, represented by Monsieur Olivier Gallezot, 51, Avenue Françoise Giroud, Parc Valmy, 21066 Dijon